Healthy Volunteers Clinical Trial
Official title:
A Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Bioequivalence of Single Oral Dose of TAK-438ASA Tablet and Single Oral Dose of TAK-438 Tablet Plus Aspirin Enteric-Coated Tablet (Study 1) and the Food Effect of Single Oral Dose of TAK-438ASA Tablet (Study 2) in Healthy Adult Male Subjects
Verified date | November 2019 |
Source | Takeda |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purposes of this study are to evaluate BE between a single-dose of TAK-438ASA tablet versus a single-dose combination of TAK-438 tablet 10 milligram (mg) and aspirin enteric-coated tablet 100 mg in Japanese healthy adult men (Study 1), and to evaluate the effects of food on the pharmacokinetics of TAK-438ASA tablet in Japanese healthy adult men (Study 2).
Status | Completed |
Enrollment | 276 |
Est. completion date | October 12, 2018 |
Est. primary completion date | October 10, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 20 Years to 60 Years |
Eligibility |
Inclusion Criteria: 1. In the opinion of the investigator or sub-investigator, participants are capable of understanding the procedures required for the study and complying with its requirements. 2. Participants sign and date an informed consent form by themselves prior to the initiation of any study procedures. 3. Japanese healthy men aged greater than or equal to (>=) 20 and less than or equal to (=<) 60, inclusive, at the time of consent. 4. Body weight >=50 kilogram (kg) as well as body mass index (BMI) >=18.5 kilogram per meter square (kg/m^2) and =<25.0 kg/m^2 at screening test. Exclusion Criteria: 1. Participants who received study drug within 16 weeks (112 days) prior to the start of study treatment in Period 1. 2. Participants who received TAK-438 or aspirin in a previous study. 3. Staffs at the study site and their family, or participants who depend on the study-related staffs at the study site (example, husband and wife, parents, children, brothers and sisters), or participants who may be constrained to consent to the study. 4. Participants with uncontrolled and clinically significant neurological, cardiovascular, lung, hepatic, renal, metabolic, gastrointestinal, urinary or endocrine disease, or other abnormalities (except for diseases investigated) that might affect the study participation or impact the results of the study. 5. Participants with a previous or current history of aspirin asthma (asthmatic attack induced by non-steroidal anti-inflammatory drugs, etc.). 6. Participants with hypersensitivity for components of TAK-438 tablet or aspirin enteric-coated tablet, or salicylic acid-based products. 7. Positive result in urinary test for illegal drug abuse at screening. 8. Participants who have a history of illegal drug abuse or alcoholism within the past 2 years prior to the screening visit, or who are not willing to refrain from alcohol consumption and drug use during the study period. 9. Participants who ingested a medicine, a supplement or food forbidden to be used in combination during the specified time period. 10. Participants with a current history or recent episodes (within the past 6 months) of gastrointestinal diseases (malabsorption, gastroesophageal reflux, peptic ulcer disease, erosive oesophagitis), frequent (at least once per week) heartburn or surgical intervention that might affect drug absorption. 11. Participants with a history of cancer, except for basal cell carcinoma in remission for >=5 years prior to Day 1. 12. Positive results at screening for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen, or serological test for syphilis. 13. Participants who have difficulties in blood draw from peripheral veins. 14. Participants who had >=200 milliliter (mL) of whole blood drawn within 4 weeks (28 days) prior to the start of study treatment in Period 1 or who had >=400 mL of whole blood drawn within 12 weeks (84 days) prior to the start of study treatment in Period 1. 15. Participants who had a total of >=800 mL of whole blood drawn within 52 weeks (364 days) prior to the start of study treatment in Period 1. 16. Participants who had blood components drawn within 2 weeks (14 days) prior to the start of study treatment in Period 1. 17. Clinically significant abnormalities in electrocardiogram at screening or admission (Day -1). 18. Participants with abnormal laboratory parameters suggestive of clinically significant underlying diseases or who have abnormal values in the following measures at screening: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) over the upper limit of normal. 19. Participants who are unlikely to comply with the protocol or deemed ineligible due to other reasons by the principal investigator or other investigators. |
Country | Name | City | State |
---|---|---|---|
Japan | Fukuoka Mirai Hospital | Fukuoka |
Lead Sponsor | Collaborator |
---|---|
Takeda |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Free Base of TAK-438 (TAK-438F) | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Primary | Study 1, Cmax: Maximum Observed Plasma Concentration for TAK-438F | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Primary | Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin | Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose | ||
Primary | Study 1, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin | Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose | ||
Secondary | Study 1, AUC8: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Secondary | Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Secondary | Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for TAK-438F | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Secondary | Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for TAK-438F | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Secondary | Study 1, AUC8: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Unchanged Aspirin | Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose | ||
Secondary | Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin | Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose | ||
Secondary | Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for Unchanged Aspirin | Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose | ||
Secondary | Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for Unchanged Aspirin | Day 1 pre-dose and at multiple time points (up to 12 hours) post-dose | ||
Secondary | Study 2, AUC8: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites (M) (M-I, M-II, M-III and M-IV-Sul) | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Secondary | Study 2, AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to Time 48 Hours Over the Dosing Interval for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul) | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Secondary | Study 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul) | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Secondary | Study 2, Cmax: Maximum Observed Plasma Concentration for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul) | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Secondary | Study 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul) | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Secondary | Study 2, T1/2z: Terminal Disposition Phase Half-life for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul) | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Secondary | Study 2, AUC8: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Unchanged Aspirin and Its Metabolite (Salicylic Acid) | Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose | ||
Secondary | Study 2, AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Over the Dosing Interval for Unchanged Aspirin and Its Metabolite (Salicylic Acid) | Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose | ||
Secondary | Study 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin and Its Metabolite (Salicylic Acid) | Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose | ||
Secondary | Study 2, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin and Its Metabolite (Salicylic Acid) | Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose | ||
Secondary | Study 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin and Its Metabolite (Salicylic Acid) | Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose | ||
Secondary | Study 2, T1/2z: Terminal Disposition Phase Half-life for Unchanged Aspirin and Its Metabolite (Salicylic Acid) | Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose | ||
Secondary | Study 2, Ae(0-48): Amount of Drug Excreted in Urine From Time 0 to 48 Hours for TAK-438F and Its Metabolites (M-I, M-II, M-III, and M-IV-Sul) | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Secondary | Study 2, Fe(0-48): Fraction of Administered Dose Excreted Into Urine From Time 0 to Time 48 Hours for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul) | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Secondary | Study 2, CLR: Renal Clearance for TAK-438F and Its Metabolites (M-I, M-II, M-III, and M-IV-Sul) | Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose | ||
Secondary | Study 2, Ae(0-24): Amount of Drug Excreted in Urine From Time 0 to 24 Hours for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid) | Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose | ||
Secondary | Study 2, Fe(0-24): Fraction of Administered Dose Excreted Into Urine From Time 0 to Time 24 Hours for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid) | Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose | ||
Secondary | Study 2, CLR: Renal Clearance for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid) | Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |